Cargando…

Mutant Oncogenes. Targets for Therapy

Detalles Bibliográficos
Autor principal:	Børresen, A.-L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Book Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968550/

Ejemplares similares

Targeting Oncogenic Mutant p53 for Cancer Therapy
por: Parrales, Alejandro, et al.
Publicado: (2015)

ONCOGENIC VIRUSES
Publicado: (1961)

The Biology of Oncogenic Viruses
por: Miller, J. George
Publicado: (1973)

Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
por: Li, Hui, et al.
Publicado: (2019)

Oncogenes and Retroviruses: Evaluation of Basic Findings and Clinical Potential
por: Frank, David A.
Publicado: (1983)

Genetic Basis for Carcinogenesis. Tumor Suppressor Genes and Oncogenes
por: Rabbitts, P.
Publicado: (1992)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

Targeting Non-Oncogene Addiction for Cancer Therapy
por: Chang, Hae Ryung, et al.
Publicado: (2021)

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
por: Staudt, Dilana, et al.
Publicado: (2018)

Oncogene addiction in gliomas: Implications for molecular targeted therapy
por: Yan, Wei, et al.
Publicado: (2011)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
por: Alkaraki, Arwa, et al.
Publicado: (2021)

Thymus and Self: Immunobiology of the Mouse Mutant Nude
por: Moore, M.
Publicado: (1977)

Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic intervention
por: Krimmer, Stefan G., et al.
Publicado: (2023)

The rebel angel: mutant p53 as the driving oncogene in breast cancer
por: Walerych, Dawid, et al.
Publicado: (2012)

Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy
por: Qi, Xiao-Mei, et al.
Publicado: (2018)

Drugging the addict: non‐oncogene addiction as a target for cancer therapy
por: Nagel, Remco, et al.
Publicado: (2016)

Resistance to Targeted Therapies Against Adult Brain Cancers
por: Amer, Neveen A.
Publicado: (2019)

Control of Nucleotide Metabolism Enables Mutant p53’s Oncogenic Gain-of-Function Activity
por: Schmidt, Valentina, et al.
Publicado: (2017)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Cancer therapy – molecular targets in tumour–host interactions
por: Kurschat, P, et al.
Publicado: (2006)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Molecular Basis of Cancer. Part A: Macromolecular Structure, Carcinogens, and Oncogenes. Part B: Macromolecular Recognition, Chemotherapy, and Immunology
por: Mockovak, Michael
Publicado: (1985)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

MicroRNA 320, an Anti-Oncogene Target miRNA for Cancer Therapy
por: Liang, Yuanyuan, et al.
Publicado: (2021)

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
por: Greulich, Heidi, et al.
Publicado: (2005)

Mutants on the Small Screen
por: Hodgkin, Jonathan
Publicado: (2004)

K-ras oncogene codon 12 point mutations in testicular cancer.
por: Ridanpää, M, et al.
Publicado: (1993)

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
por: Naramura, Mayumi, et al.
Publicado: (2011)

Thrombopoietin receptor is required for the oncogenic function of CALR mutants
por: Nivarthi, H, et al.
Publicado: (2016)

Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment
por: Neely, Victoria, et al.
Publicado: (2023)

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
por: Torti, Davide, et al.
Publicado: (2011)

How should we define STAT3 as an oncogene and as a potential target for therapy?
por: Sellier, Hélène, et al.
Publicado: (2013)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

Targeting mutant p53 for cancer therapy: direct and indirect strategies
por: Hu, Jiahao, et al.
Publicado: (2021)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Oncogenes in immune cells as potential therapeutic targets
por: Zakiryanova, Gulnur K, et al.
Publicado: (2018)

Targeting Oncogenic BRAF: Past, Present, and Future
por: Zaman, Aubhishek, et al.
Publicado: (2019)

Targeting oncogenic Notch signaling with SERCA inhibitors
por: Pagliaro, Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_53va5s8irr7grvkp9ppf6can7j